21 patents
Utility
Compositions and methods for treating cancer
27 Dec 22
Disclosed are methods for treating cancer by reduction of glycogen stores and administering tyrosine derivatives.
Steven Hoffman
Filed: 14 May 20
Utility
Tyrosine Derivatives and Compositions Comprising Them
6 Oct 22
Compositions and kits comprising a tyrosine hydroxylase inhibitor and an anticancer agent that is chemically bonded to, or physically associated with, the tyrosine hydroxylase inhibitor are provided.
Steven HOFFMAN
Filed: 23 Jun 22
Utility
D-metyrosine Compositions and Methods for Preparing Same
26 May 22
John ZUCARO
Filed: 18 Mar 20
Utility
Crystalline Forms of Metyrosine
6 Jan 22
The disclosure provides crystalline compositions comprising D-metyrosine and L-metyrosine, pharmaceutical formulation comprising one or more crystalline composition described herein and a pharmaceutically acceptable excipient, methods for treating cancer in a patient in need thereof, the method comprising administering to the patient one or more composition described herein, and methods for preparing the compositions described herein.
John Zucaro
Filed: 1 Jul 21
Utility
Pharmaceutical Compositions And Methods
16 Dec 21
Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided.
Steven Hoffman
Filed: 30 Aug 21
Utility
Pharmaceutical Compositions and Methods
9 Dec 21
Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided.
Steven Hoffman
Filed: 2 Jul 21
Utility
Methods of Treating SARS-COV-2 Infections
18 Nov 21
The disclosure is directed to methods of using TUDCA, or a pharmaceutically acceptable salt thereof, or a derivative thereof, for the treatment of SARS-CoV-2 infections.
Steven Hoffman, John Rothman
Filed: 6 Jan 21
Utility
Tumor Reduction Formulations and Methods of Use Thereof
9 Sep 21
The invention relates to tumor reducing compositions and methods thereof.
Steven Hoffman, John Rothman
Filed: 2 Jul 19
Utility
Pharmaceutical compositions and methods
31 Aug 21
Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided.
Steven Hoffman
Filed: 10 Apr 20
Utility
High-speed centrifugal mixing devices and methods of use
24 Aug 21
A centrifugal mixing device can include a shaft assembly that is operably coupled to a motor such that the motor rotates the shaft assembly about a first axis.
Steven Hoffman
Filed: 28 Jun 17
Utility
Compositions And Methods For Modulating Cancer
22 Jul 21
The present inventions provide compositions and methods for modulating cancer using a tyrosine derivative.
Steven Hoffman
Filed: 15 Jan 21
Utility
Tyrosine derivatives and compositions comprising them
13 Jul 21
Provided herein are methods comprising providing a tyrosine derivative and a solid particulate material (and, optionally, melanin) and applying force to said tyrosine derivative and said solid particulate material for a time and under conditions effective to impregnate at least one of said tyrosine derivative and said solid particulate material with the other of said tyrosine derivative and said solid particulate material.
Steven Hoffman
Filed: 6 Mar 17
Utility
Pharmaceutical compositions and methods
6 Jul 21
Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided.
Steven Hoffman
Filed: 11 Dec 19
Utility
Pharmaceutical Compositions and Methods
10 Jun 21
Methods of treating cancer or reducing tumor size by contacting a patient's cancer cells or tumor with an effective amount of a pharmaceutical composition as further defined herein.
Steven Hoffman, John Rothman
Filed: 9 Dec 20
Utility
Methods of treating SARS-COV-2 infections
2 Feb 21
The disclosure is directed to methods of using TUDCA, or a pharmaceutically acceptable salt thereof, or a derivative thereof, for the treatment of SARS-CoV-2 infections.
Steven Hoffman, John Rothman
Filed: 6 Jul 20
Utility
Transdermal Formulations
30 Dec 20
The present disclosure is directed to transdermal compositions comprising isothiocyanates or isocyanates.
Steven HOFFMAN
Filed: 13 Sep 18
Utility
Compositions and Methods for Treating Cancer
18 Nov 20
The present invention provides methods for treating cancer.
Steven Hoffman
Filed: 13 May 20
Utility
Pharmaceutical Compositions for the Treatment of Cancer
4 Nov 20
The present disclosure provides methods, compositions, and kits for treating cancer using a combination of L-rhamnose and a leucine aminopeptidase inhibitor.
Steven HOFFMAN
Filed: 16 Jul 20
Utility
Pharmaceutical compositions and methods
11 May 20
Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided.
Steven Hoffman
Filed: 22 May 19
Utility
Pharmaceutical Compositions and Methods
8 Apr 20
Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided.
Steven Hoffman
Filed: 10 Dec 19